Carriage of Neisseria meningitidis among travelers attending the Hajj pilgrimage, circulating serogroups, sequence types and antimicrobial susceptibility: A multinational longitudinal cohort study

Travel Med Infect Dis. 2023 May-Jun:53:102581. doi: 10.1016/j.tmaid.2023.102581. Epub 2023 May 12.

Abstract

Background: Travel to international mass gatherings such as the Hajj pilgrimage increases the risk of Neisseria meningitidis transmission and meningococcal disease. We investigated carriage and acquisition of N. meningitidis among travelers to Hajj and determined circulating serogroups, sequence types and antibiotic susceptibility among isolates.

Method: We conducted a multinational longitudinal cohort study among 3921 traveling pilgrims in two phases: Pre-Hajj and Post-Hajj. For each participant, a questionnaire was administered and an oropharyngeal swab was obtained. N. meningitidis was isolated, serogrouped, and subjected to whole genome sequence analysis and antibiotic susceptibility testing.

Results: Overall carriage and acquisition rates of N. meningitidis were 0.74% (95%CI: 0.55-0.93) and 1.10% (95%CI: 0.77-1.42) respectively. Carriage was significantly higher Post-Hajj (0.38% vs 1.10%, p = 0.0004). All isolates were nongroupable, and most belonged to the ST-175 complex and were resistant to ciprofloxacin with reduced susceptibility to penicillins. Three potentially invasive isolates (all genogroup B) were identified in the Pre-Hajj samples. No factors were associated with Pre-Hajj carriage. Suffering influenza like illness symptoms and sharing a room with >15 people were associated with lower carriage Post-Hajj (adjOR = 0.23; p = 0.008 and adjOR = 0.27; p = 0.003, respectively).

Conclusion: Carriage of N. meningitidis among traveler attending Hajj was low. However, most isolates were resistant to ciprofloxacin used for chemoprophylaxis. A review of the current meningococcal disease preventive measures for Hajj is warranted.

Keywords: Antibiotic resistance; Mass gatherings; Meningococcal disease; Public health; Travel; Vaccine.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Carrier State / epidemiology
  • Ciprofloxacin / therapeutic use
  • Cohort Studies
  • Humans
  • Longitudinal Studies
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / prevention & control
  • Neisseria meningitidis* / genetics
  • Saudi Arabia / epidemiology
  • Serogroup

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Ciprofloxacin